Investors Three-year Losses Continue as BGI Genomics (SZSE:300676) Dips a Further 9.0% This Week, Earnings Continue to Decline
Investors Three-year Losses Continue as BGI Genomics (SZSE:300676) Dips a Further 9.0% This Week, Earnings Continue to Decline
If you love investing in stocks you're bound to buy some losers. But long term BGI Genomics Co., Ltd. (SZSE:300676) shareholders have had a particularly rough ride in the last three year. Unfortunately, they have held through a 64% decline in the share price in that time. Shareholders have had an even rougher run lately, with the share price down 17% in the last 90 days. However, one could argue that the price has been influenced by the general market, which is down 8.2% in the same timeframe.
如果你喜欢投资股票,你一定会买一些输家。但是从长远来看 华大基因株式会社 (深交所股票代码:300676)股东在过去三年中经历了特别艰难的经历。不幸的是,在那段时间里,他们的股价一直下跌了64%。最近,股东们的表现更加艰难,股价在过去90天内下跌了17%。但是,有人可能会争辩说,价格受到了大盘的影响,同期下跌了8.2%。
If the past week is anything to go by, investor sentiment for BGI Genomics isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
如果说过去一周有什么好处,那么投资者对华大基因组学的情绪并不乐观,所以让我们看看基本面和股价之间是否存在不匹配的情况。
See our latest analysis for BGI Genomics
查看我们对华大基因组学的最新分析
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
虽然市场是一种强大的定价机制,但股价反映了投资者的情绪,而不仅仅是潜在的业务表现。考虑市场对公司的看法发生了怎样的变化的一种不完美但简单的方法是将每股收益(EPS)的变化与股价走势进行比较。
During the three years that the share price fell, BGI Genomics' earnings per share (EPS) dropped by 48% each year. This fall in the EPS is worse than the 29% compound annual share price fall. So the market may not be too worried about the EPS figure, at the moment -- or it may have previously priced some of the drop in. This positive sentiment is also reflected in the generous P/E ratio of 79.62.
在股价下跌的三年中,华大基因的每股收益(EPS)每年下降48%。每股收益的下跌比股价年复合下跌29%还要严重。因此,市场目前可能不太担心每股收益的数字,或者它此前可能已经将部分下跌定为下跌。这种积极的情绪也反映在79.62的丰厚市盈率上。
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
你可以在下面看到 EPS 是如何随着时间的推移而变化的(点击图片发现确切的值)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231021/0-bf76230dddbc18804299d0d79501d409-0-af2dff3df007ab41e0ed36e538b39021.png/big)
Dive deeper into BGI Genomics' key metrics by checking this interactive graph of BGI Genomics's earnings, revenue and cash flow.
查看这张华大基因的收益、收入和现金流的交互式图表,深入了解华大基因的关键指标。
A Different Perspective
不同的视角
While the broader market lost about 5.8% in the twelve months, BGI Genomics shareholders did even worse, losing 14% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 0.5% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that BGI Genomics is showing 3 warning signs in our investment analysis , and 2 of those are potentially serious...
尽管整个市场在十二个月内下跌了约5.8%,但华大基因的股东表现更糟,下跌了14%(甚至包括股息)。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。遗憾的是,去年的业绩结束了糟糕的表现,股东们在五年内每年面临0.5%的总亏损。我们意识到,罗斯柴尔德男爵曾表示,投资者应该 “在街上流血时买入”,但我们提醒说,投资者应首先确保他们购买的是高质量的企业。我发现从长远来看,将股价作为业务表现的代表非常有趣。但是,为了真正获得洞察力,我们还需要考虑其他信息。即便如此,请注意华大基因组学正在显示 我们的投资分析中有3个警告信号 ,其中有两个可能很严重...
Of course BGI Genomics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然 华大基因可能不是最值得买入的股票。所以你可能希望看到这个 免费的 成长型股票的收集。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。